Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use

Inclusion Criteria: * 1\) histologically confirmed high-grade sarcoma; * 2\) initial treatment in the orthopedic oncology departments of the three affiliated hospitals of Peking University; * 3\) tumors not amenable to curative treatment or inclusion in clinical trials; * 4\) unresectable local advanced lesions or multiple metastatic lesions that could not be cured by local therapy; * 5\) measurable lesions according to Response Evaluation Criteria for Solid Tumors (RECIST1.1) \[8\]; * 6\) Eastern Cooperative Oncology Group performance status 0 or 1 \[9\]; and 7) acceptable hematologic, hepatic, and renal function. Exclusion Criteria: * had been previously exposed to other TKIs; * had central nervous system metastasis; * had other kinds of malignant tumors at the same time; had cardiac insufficiency or arrhythmia; * had uncontrolled complications such as diabetes mellitus, coagulation disorders, urine protein ≥ ++ and so on; * had pleural or peritoneal effusion that needs to be handled by surgical treatment; * combined with other infections or wounds * were pregnant or breastfeeding.